Bi-allelic EPHA2 mutations cause dysosteosclerosis by inhibiting osteoclastogenesis and enhancing osteoblastogenesis

Abstract

Erythropoietin-producing hepatocellular (EPH) receptors, the largest receptor tyrosine kinase family, have been shown to play a crucial role in normal physiological processes and pathologies. EPHA2, encoded by EPHA2 gene, a member of the EPH receptor family, has been implicated in cataracts and various bone tumors, including osteosarcoma, chondrosarcoma, and bone metastases of breast cancer. However, no association between the EPHA2 gene and genetic skeletal disorders has been reported to date. Here, we identified a Chinese family with a diagnosis of dysosteosclerosis, presenting with significant increase in lumbar spine bone mineral density, multifocal sclerotic lesions throughout the body, sclerotic skull, platyspondyly and sandwich vertebrae, and demonstrated compound heterozygous mutations in EPHA2 gene (c.890 C > T, p.Thr297Met; c.988dupT, p.Ser330PhefsX51). We observed a reduction in numerous sclerotic lesions in patients during the five-year follow-up. To systematically investigate the molecular mechanisms of pathogenesis, we employed a range of methodologies, including in vitro cellular assays, genome-wide association studies analysis, induced pluripotent stem cells models and Epha2 knockout mice models. We have determined that loss-of-function mutations in EPHA2 gene lead to dysosteosclerosis through enhancing mesenchymal stem cells osteogenic differentiation and downregulating the p38-MAPK pathway, leading to decreased osteoclast differentiation. Consequently, we proposed and validated EPHA2 as a viable therapeutic target for osteoporosis by constructing femoral fracture mice models and ovariectomized mice models. In summary, this study identifies bi-allelic loss-of-function mutations in EPHA2 gene lead to dysosteosclerosis and its underlying mechanisms, and suggests EPHA2 as a potential therapeutic target for osteoporosis.

References

[1] Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol. Med., 2005, 11: 76-81.

[2] Li C, et al. The osteoprotective role of USP26 in coordinating bone formation and resorption. Cell Death Differ., 2022, 29: 1123-1136.

[3] Boudin E, Van Hul W. Sclerosing bone dysplasias. Best. Pr. Res. Clin. Endocrinol. Metab., 2018, 32: 707-723.

[4] Ihde LL, et al. Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. Radiographics, 2011, 31: 1865-1882.

[5] Sun S, et al. Osteopetrosis-like disorders induced by osteoblast-specific retinoic acid signaling inhibition in mice. Bone Res., 2024, 12: 61.

[6] Unger S, et al. Nosology of genetic skeletal disorders: 2023 revision. Am. J. Med. Genet. A, 2023, 191: 1164-1209.

[7] Whyte MP, et al. Dysosteosclerosis presents as an “osteoclast-poor” form of osteopetrosis: comprehensive investigation of a 3-year-old girl and literature review. J. Bone Miner. Res., 2010, 25: 2527-2539.

[8] Guo L, et al. Dysosteosclerosis is also caused by TNFRSF11A mutation. J. Hum. Genet., 2018, 63: 769-774.

[9] Teti A, Whyte MP. Osteopetrosis: gene-based nosology and significance. Bone, 2023, 175. 116854

[10] Uludağ Alkaya D, Akpınar E, Bilguvar K, Tüysüz B. Resolution of sclerotic lesions of dysosteosclerosis due to biallelic SLC29A3 variant in a Turkish girl. Am. J. Med. Genet. A, 2021, 185: 2271-2277.

[11] Campeau PM, et al. Whole-exome sequencing identifies mutations in the nucleoside transporter gene SLC29A3 in dysosteosclerosis, a form of osteopetrosis. Hum. Mol. Genet., 2012, 21: 4904-4909.

[12] Howaldt A, et al. Sclerosing bone dysplasias with hallmarks of dysosteosclerosis in four patients carrying mutations in SLC29A3 and TCIRG1. Bone, 2019, 120: 495-503.

[13] Guo L, et al. Bi-allelic CSF1R mutations cause skeletal dysplasia of dysosteosclerosis-pyle disease spectrum and degenerative encephalopathy with brain malformation. Am. J. Hum. Genet., 2019, 104: 925-935.

[14] Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell, 2008, 133: 38-52.

[15] Matsuo K, Otaki N. Bone cell interactions through Eph/ephrin: bone modeling, remodeling and associated diseases. Cell Adh Migr., 2012, 6: 148-156.

[16] Edwards CM, Mundy GR. Eph receptors and ephrin signaling pathways: a role in bone homeostasis. Int. J. Med. Sci., 2008, 5: 263-272.

[17] Zhao C, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab., 2006, 4: 111-121.

[18] Rodríguez-Sosa, M. R., Del Castillo, L. M., Belarra, A., Zapata, A. G. & Alfaro, D. The lack of EphB3 receptor prevents bone loss in mouse models of osteoporosis. J. Bone Miner. Res.53, 1008–1024 (2024).

[19] Wang, Y. et al. Ablation of Ephrin B2 in Col2 expressing cells delays fracture repair. Endocrinology161, bqaa179 (2020).

[20] Arthur A, et al. EphB/ephrin-B interactions mediate human MSC attachment, migration and osteochondral differentiation. Bone, 2011, 48: 533-542.

[21] Xiao T, et al. Targeting EphA2 in cancer. J. Hematol. Oncol., 2020, 13: 114.

[22] Wilson K, Shiuan E, Brantley-Sieders DM. Oncogenic functions and therapeutic targeting of EphA2 in cancer. Oncogene, 2021, 40: 2483-2495.

[23] Dave A, et al. Genotype, Age, Genetic Background, and Sex Influence Epha2-Related Cataract Development in Mice. Invest Ophthalmol. Vis. Sci., 2021, 62: 3.

[24] Harding, P. et al. EPHA2 segregates with microphthalmia and congenital cataracts in two unrelated families. Int. J. Mol. Sci.22, 2190 (2021).

[25] Movérare-Skrtic, S. et al. Identification of ephrin-A1-EphA2 signalling as a potential target for fracture prevention. Nat. Commun.17, 1988 (2026).

[26] Irie N, et al. Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis. J. Biol. Chem., 2009, 284: 14637-14644.

[27] Liu L, et al. 17β-estradiol attenuates ovariectomy‑induced bone deterioration through the suppression of the ephA2/ephrinA2 signaling pathway. Mol. Med. Rep., 2018, 17: 1609-1616

[28] Ren L, et al. MiR-210 promotes bone formation in ovariectomized rats by regulating osteogenic/adipogenic differentiation of bone marrow mesenchymal stem cells through downregulation of EPHA2. J. Orthop. Surg. Res, 2023, 18: 811.

[29] Hui, L., Cheng-ye, J., Xin-nan, Z. & Ya-qin, Z. Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years. Chinese J. Pediatr.47, 487–492 (2009).

[30] Xiyu, W. et al. Differences in male and female children and adolescents of acquisition with bone density in Changsha. Chinese J. Osteopor.23, 253–260 (2008).

[31] Zhang Y, et al. Variation of bone turnover markers in childhood and adolescence. Int. J. Clin. Pr., 2023, 20235537182

[32] Qian, Y. et al. Genome-wide association studies of over 30 000 samples with bone mineral density at multiple skeletal sites and its clinical relevance. Genom. Proteom. Bioinform.23, qzaf097 (2025).

[33] Beresford JN, Bennett JH, Devlin C, Leboy PS, Owen ME. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J. Cell Sci., 1992, 102Pt 2341351.

[34] Sabokbar A, Mahoney DJ, Hemingway F, Athanasou NA. Non-canonical (RANKL-independent) pathways of osteoclast differentiation and their role in musculoskeletal diseases. Clin. Rev. Allergy Immunol., 2016, 51: 16-26.

[35] Zhang T, et al. Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal dominant congenital cataract. Hum. Mutat., 2009, 30: E603E611.

[36] Vincenzi M, Mercurio FA, Leone M. Cataract-related mutations in EphA2: a survey of literature data and the relevance of the receptor Sam domain. Expert Opin. Ther. Targets, 2025, 29: 239-265.

[37] Jun G, et al. EPHA2 is associated with age-related cortical cataract in mice and humans. PLoS Genet., 2009, 5: e1000584.

[38] O’Neal WT, et al. Deletion of the EphA2 receptor exacerbates myocardial injury and the progression of ischemic cardiomyopathy. Front. Physiol., 2014, 5: 132

[39] Chen X, et al. Vitamin D status and its associations with bone mineral density, bone turnover markers, and parathyroid hormone in Chinese postmenopausal women with osteopenia and osteoporosis. Front. Nutr., 2023, 10. 1307896

[40] Wei Z, et al. Mutations in profilin 1 cause early-onset Paget’s disease of bone with giant cell tumors. J. Bone Miner. Res, 2021, 36: 1088-1103.

[41] Qian Y, et al. Observational and genetic evidence highlight the association of human sleep behaviors with the incidence of fracture. Commun. Biol., 2021, 4: 1339.

[42] Zhao P, et al. Shared genetic architecture highlights the bidirectional association between major depressive disorder and fracture risk. Gen. Psychiatr., 2024, 37. e101418

[43] Bai WY, et al. Integrative analysis of genomic and epigenomic data reveal underlying superenhancer-mediated microRNA regulatory network for human bone mineral density. Hum. Mol. Genet., 2021, 30: 2177-2189.

[44] Bycroft C, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature, 2018, 562: 203-209.

[45] Chou WC, et al. A combined reference panel from the 1000 Genomes and UK10K projects improved rare variant imputation in European and Chinese samples. Sci. Rep., 2016, 6. 39313

[46] Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics, 2010, 26: 2190-2191.

[47] Gu H, et al. Optimizing the method for generation of integration-free induced pluripotent stem cells from human peripheral blood. Stem Cell Res Ther., 2018, 9: 163.

[48] Xu S, et al. Endoplasmic reticulum stress causes long bone shortening in P4hb(C402R/+) mice: a mouse model exhibiting significant features of cole-carpenter syndrome driven by P4HB mutations. Biochim Biophys. Acta Mol. Basis Dis., 2025, 1871. 167663

Funding

National Natural Science Foundation of China (National Science Foundation of China)(82300985)

Rights & permissions

The Author(s)